From Sequence To Scale In Seven Months: The EntoEngine™ Achieves Rapid Commercial Scale With Stable Strains

Bringing a recombinant protein from sequence selection to commercial manufacturing is often slowed by one critical challenge: establishing stable, scalable expression. Traditional cell line development can require months of clone screening, optimization, and scale-up before production targets are reached. This case study explores an alternative path to commercialization, demonstrating how stable expression and manufacturing scale can be achieved in parallel through a transgenic Drosophila melanogaster platform.

Using human prolactin (PRL) as a model protein, the process progressed from sequence to commercial-scale production in just seven months while maintaining product quality, biological activity, safety, and batch consistency. The study highlights key considerations in biomanufacturing scale-up, including genetic stability, reproducibility, production timelines, and cost efficiency. Results include validated purity, receptor-binding activity, bioactivity, and glycosylation profiles across multiple manufacturing lots.

For organizations evaluating alternatives to conventional cell culture systems, these findings offer practical insight into how manufacturing strategies can influence speed to scale, operational flexibility, and long-term production reliability.